Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)
22 Febrero 2024 - 6:00AM
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a
clinical-stage biopharmaceutical company focused on advancing novel
oral therapies that address a broad range of inflammatory diseases
with significant unmet medical need, today announced that data from
the Phase 2 trial of VTX002 in ulcerative colitis will be presented
during the 19th Congress of the European Crohn's and Colitis
Organisation (ECCO) on February 22, 2024, in Stockholm,
Sweden.
“We are very excited to present the results of
the VTX002 Phase 2 trial in ulcerative colitis during the 19th
Congress of the European Crohn’s and Colitis Organisation,” said
Raju Mohan, Chief Executive Officer. “We believe these data
establish VTX002 as a highly attractive oral therapy for UC based
on its compelling efficacy profile, including a potentially
differentiated rate of endoscopic remission and
histologic-endoscopic mucosal improvement, and its potential
best-in-class safety profile.”
Oral Presentation Details:
Title: "Efficacy and safety of
the oral selective sphingosine-1-phosphate-1 receptor modulator
VTX002 in moderately to severely active Ulcerative Colitis: results
from a randomised, double-blind, placebo-controlled, phase 2
trial”Presenter: Bruce E. Sands, M.D., M.S.; Dr.
Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D.
Janowitz Division of Gastroenterology, Icahn School of Medicine,
Mount Sinai, NYSession: Crossing borders in IBD:
Session 1 - IBD therapy - crossing
bordersDate/Time: Thursday, February 22, 2024,
13:30 - 13:40 (CET)Session Hall: Plenary Hall
Slides will be available following the oral
presentation in the Investors section of the company’s website at
www.ventyxbio.com.
About Ventyx Biosciences
Ventyx is a clinical-stage biopharmaceutical
company focused on developing innovative oral medicines for
patients living with autoimmune and inflammatory disorders. We
believe our ability to efficiently discover and develop
differentiated drug candidates will allow us to address important
unmet medical need with novel oral therapies that can shift
immunology markets from injectable to oral drugs. Our current
pipeline includes internally discovered clinical programs targeting
TYK2, S1P1R and NLRP3, positioning us to become a leader in the
development of oral immunology therapies. Ventyx is headquartered
in San Diego, California. For more information about Ventyx, please
visit www.ventyxbio.com.
Forward-Looking Statements
Ventyx cautions you that statements contained in
this press release regarding matters that are not historical facts
are forward-looking statements. These statements are based on
Ventyx’s current beliefs and expectations. Such forward-looking
statements include, but are not limited to, statements regarding:
the potential of Ventyx’s product candidates and the anticipated
continued progression of the development pipeline for such product
candidates; and the therapeutic and commercial potential of VTX002
in ulcerative colitis, including its efficacy profile, potential as
a best-in-disease oral agent and its potential best-in-class safety
profile. The inclusion of forward-looking statements should not be
regarded as a representation by Ventyx that any of its plans will
be achieved. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in
Ventyx’s business, including, without limitation: potential delays
in the commencement, enrollment and completion of clinical trials;
Ventyx’s dependence on third parties in connection with product
manufacturing, research and preclinical and clinical testing;
disruptions in the supply chain, including raw materials needed for
manufacturing and animals used in research, delays in site
activations and enrollment of clinical trials; the results of
preclinical studies; early clinical trials not necessarily being
predictive of future results; interim results not necessarily being
predictive of final results; the potential of one or more outcomes
to materially change as a trial continues and more patient data
become available and following more comprehensive audit and
verification procedures; regulatory developments in the United
States and foreign countries; unexpected adverse side effects or
inadequate efficacy of Ventyx’s product candidates that may limit
their development, regulatory approval and/or commercialization, or
may result in recalls or product liability claims; Ventyx’s ability
to obtain and maintain intellectual property protection for its
product candidates; the use of capital resources by Ventyx sooner
than expected; disruption to Ventyx’s operations from the ongoing
military conflicts in Ukraine and the Middle East, including
clinical trial delays; and other risks described in Ventyx’s prior
press releases and Ventyx’s filings with the Securities and
Exchange Commission (SEC), including in Part II, Item 1A (Risk
Factors) of Ventyx’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2023, filed on or about November 9,
2023, and any subsequent filings with the SEC. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof, and Ventyx undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, which is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Investor Relations ContactPatti BankManaging
DirectorICR Westwicke(415) 513-1284IR@ventyxbio.com
Ventyx Biosciences (NASDAQ:VTYX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Ventyx Biosciences (NASDAQ:VTYX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024